Acumen Pharmaceuticals (NASDAQ:ABOS) Insider Eric Siemers Sells 6,834 Shares

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) insider Eric Siemers sold 6,834 shares of the business’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $1.97, for a total transaction of $13,462.98. Following the sale, the insider directly owned 159,464 shares in the company, valued at $314,144.08. This trade represents a 4.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Eric Siemers also recently made the following trade(s):

• On Monday, January 5th, Eric Siemers sold 4,000 shares of Acumen Pharmaceuticals stock. The stock was sold at an average price of $1.96, for a total value of $7,840.00.

Acumen Pharmaceuticals Stock Performance

Shares of ABOS opened at $1.99 on Thursday. The stock has a 50-day moving average of $1.96 and a two-hundred day moving average of $1.67. Acumen Pharmaceuticals, Inc. has a one year low of $0.86 and a one year high of $2.46. The company has a debt-to-equity ratio of 0.29, a quick ratio of 6.02 and a current ratio of 6.02. The stock has a market cap of $120.53 million, a P/E ratio of -0.90 and a beta of 0.23.

Acumen Pharmaceuticals (NASDAQ:ABOS) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.19. As a group, research analysts predict that Acumen Pharmaceuticals, Inc. will post -1.56 EPS for the current year.

Key Stories Impacting Acumen Pharmaceuticals

Here are the key news stories impacting Acumen Pharmaceuticals this week:

• Negative Sentiment: CEO Daniel J. O’Connell sold three blocks between Jan. 5–7 totaling 47,506 shares (largest single-day block ~37,755 on Jan. 7), reducing his stake by ~5.7% and raising roughly $75k on the largest sale. CEO still holds a sizable position (~620k shares). SEC Filing
• Negative Sentiment: CFO Matt Zuga sold three tranches on Jan. 5–7 totaling 14,905 shares (~1.73%–2.61% reductions per trade), raising roughly $29k across the period and leaving him with ~216k–227k shares. SEC Filing
• Negative Sentiment: COO Russell Barton sold three tranches on Jan. 5–7 totaling 9,318 shares, trimming his holding by a few percent and raising roughly $18k. SEC Filing
• Negative Sentiment: Insider Eric Siemers sold two tranches (4,000 and 6,834 shares) on Jan. 5–6, reducing his stake by ~2–4% and raising ~ $21k. SEC Filing

Institutional Trading of Acumen Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Hudson Bay Capital Management LP grew its position in Acumen Pharmaceuticals by 7.1% during the second quarter. Hudson Bay Capital Management LP now owns 825,004 shares of the company’s stock valued at $957,000 after buying an additional 55,004 shares during the period. SG Americas Securities LLC acquired a new position in shares of Acumen Pharmaceuticals in the third quarter worth about $691,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Acumen Pharmaceuticals during the 2nd quarter worth about $291,000. Susquehanna International Group LLP grew its position in shares of Acumen Pharmaceuticals by 26.5% during the 3rd quarter. Susquehanna International Group LLP now owns 214,440 shares of the company’s stock valued at $367,000 after acquiring an additional 44,902 shares during the period. Finally, Bank of America Corp DE increased its stake in shares of Acumen Pharmaceuticals by 45.4% in the 3rd quarter. Bank of America Corp DE now owns 213,729 shares of the company’s stock valued at $365,000 after purchasing an additional 66,720 shares in the last quarter. 71.01% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ABOS has been the topic of several recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a report on Tuesday, October 14th. Wall Street Zen raised shares of Acumen Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, December 21st. Finally, Bank of America cut their price target on Acumen Pharmaceuticals from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Acumen Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $6.75.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.